Approaching the Finish line: CGRP Inhibitors
For the last few years we’ve been watching the race to get CGRP inhibitors on the market for migraine prevention. Well, you could be seeing those drugs approved as early as next year. What’s the latest?
First, if you need to review exactly what CGRP inhibitors are, check out The Secret of CGRP.
Leading the pack at the moment is erenumab, also known as AMG 334. In September, the report said that 70mg of erenumab, delivered by injection, had almost 3 fewer days of migraine attacks per month. These are episodic migraine sufferers who originally had between 4 and 14 migraine days per month. That means that if you could have about 30% fewer attacks, and side effects seem to be few.
Erenumab now moves into the second part of the trial, testing different dosages over 24 weeks.
Also in Phase III trials is galcanezumab, also known as LY2951742. Galcanezumab also had statistically significant results in previous trials, with a once-a-month injection, and participants are currently being recruited for new trials – those with chronic and episodic migraine, and those with chronic and episodic cluster headache – for more information visit ClinicalTrials.gov.
A little further behind, but possibly the one to watch in 2018, is TEV-48125. A once-monthly injection at various doses was tried, and as early as 3 days into the treatment patients had positive results. Studies continue for both chronic and episodic migraine.
Finally, let’s not leave out ALD403. ALD403 is well on its way for treatment of episodic and chronic migraine, though the episodic migraine trials are further along.
Many patients taking ALD403 in trials actually experienced a complete remission of migraine, and others a significant decrease. Trials continue.
These are just tidbits of information about the trials, and they really can’t be compared at this point, even if we did have all trial data. The point is that these still look like solid options to prevent episodic and chronic migraine, and even cluster. Some if not all of these should roll out over the next 2-3 years, and by that time we’ll know them better.
For more information, see:
- Clinical Data Presented at American Headache Society Meeting Shows Promise of New Treatments for Migraine Prevention
- CGRP Drug Works Fast in Chronic Migraine (TEV-48125)
- Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field (erenumab)
- Migraine data for Amgen
- Numerous anticipated clinical milestones (ALD403)
- Lilly CLINICAL DEVELOPMENT PIPELINE (galcanezumab)